Guardant Health

GH

Market cap $12.5B

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and cancer advocate Patrick Dempsey to increase awareness about colorectal cancer (CRC) screening and the Shield® blood test. Approved by the U.S. Food and Drug Administration (FDA) in 2024 and recommended in national guidelines, Shield offers an easier way to screen for colorectal cancer (CRC) with just a blood draw for eligible individuals 45.

Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring Health Services reported another strong quarter with both revenues and EBITDA up significantly, far outpacing its historical growth rate prior to going public in 2024. Varonis Systems, which provides data protection security software, delivered disappointing earnings results and an outlook below expectations.

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 41,852 shares of its common stock to 88 new non-executive employees and one non-qualified stock option award to purchase 4,965 shares of its common stock to one new non-executive employee with a grant date of Februar.

Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetization. The Russell 1000 Value Index returned 3.81% during the quarter, outperforming the Russell 1000 Growth Index's return of 1.12% by nearly 270 basis points. Under its 'pivot to growth' strategy, Teva has expanded its biosimilars portfolio and strengthened its generics business, returning that segment to positive growth.

Allspring Mid Cap Growth Fund Q4 2025 Performance Insights, Portfolio Drivers & Decisions

Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Guardant Health (GH) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.62 per share a year ago.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $281.3 million, an increase of 39%, driven by: Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests.

IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Walmart, Guardant Health and Quanta Services. Check out our daily newsletter!